
Supernus Pharmaceuticals is an award-winning biopharmaceutical company with more than 30 years of experience in developing and commercializing products that treat central nervous system (CNS) diseases. At Supernus, we develop innovative products that help treat neurological and psychiatric conditions. At Supernus, we develop innovative products that help treat neurological and psychiatric conditions. We currently have 8 products in the market that are making a real impact on patient outcomes.
The Senior Medical Science Liaison is a Medical Affairs professional that is dedicated to bridging the gap between Supernus and the medical community. This role functions as a scientific expert, educating healthcare professionals (HCPs), building relationships with Key Opinion Leaders (KOLs), and collecting real-world insights on Attention-Deficit/Hyperactivity Disorder, Depressive Disorders, other neuropsychiatric conditions, and treatment.
Essential Duties & Responsibilities:
Supervisory Responsibilities:
Knowledge & Other Qualifications:
Other Characteristics:
Physical Requirements/Work Environment/Travel Requirements:
Compensation:
At Supernus, we offer a competitive compensation package that reflects your experiences and contributions. The expected salary range for fully qualified candidates applying for this role is $170,000 to $194,000. This range is what the Company reasonably expects to offer for the position and is not reflective of the full compensation scale of the role. This range may be modified in the future. An individual’s salary within the range is based on multiple factors, which may include and are not limited to education, relevant experience, knowledge, length of industry experience and organizational needs.
You also will be able to participate in a competitive benefits package, including but not limited to: health, dental, vision, paid time off, 401k company match, company paid life insurance and health and wellness benefits. The total compensation package for this position also includes other compensation elements such as stock equity awards, employee stock purchase programs and participation in our Company’s discretionary annual bonus program.
Supernus Pharmaceuticals is an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, national origin, disability, protected veteran status, age or any other characteristic protected by law.

We are a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Our extensive expertise in product development has been built over the past 30 years: initially as a standalone development organization, then as a U.S. subsidiary of Shire plc and, in late 2005, as Supernus Pharmaceuticals Inc. We market our products in the United States through our own specialty sales force and seek strategic collaborations with other pharmaceutical companies to license our products outside the United States.
We market Qelbree® (viloxazine extended-release) for the treatment of attention deficit/hyperactivity disorder (ADHD) in children ages 6 to 17. Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy, Apokyn® (apomorphine hydrochloride injection) for the acute treatment of hypomobility in advanced Parkinson’s disease (PD), Myobloc® (rimabotulinumtoxinB) for the treatment of cervical dystonia and treatment of chronic sialorrhea in adults, and Xadago® (safinamide) as an adjunctive treatment to levodopa/carbidopa in PD patients with hypomobility.
We are also developing several product candidates to address large market opportunities in the CNS market, including SPN-812 for the treatment of ADHD in adults, apomorphine infusion pump for hypomobility in PD, SPN-820 (NV-5138) for treatment-resistant depression, and SPN-817 for the treatment of epilepsy.